This meta-analysis aimed to assess the effectiveness of moist exposed burn ointment (MEBO) for diabetic foot ulcers (DFU). Two researchers independently assessed the quality and validity of included randomized controlled trials (RCTs) in 7 electronic databases. Risk of bias was assessed using Cochrane handbook guidelines. Twenty seven trials which include 1,979 patients were involved for analysis. Comparison of the same intervention strategies revealed significant differences in total effectiveness rates between BEBO and conventional therapy group (Risk Ratio [RR], 6.36, [95% confidence interval (CI), 3.20, 12.64], P < 0.00001); MEBO combined with standard therapy (Risk Ratio [RR], 1.19, [95% confidence interval (CI), 1.08, 1.31], P = 0.0007); and healing time of DFU (Mean Difference [MD], 14.15, [95% confidence interval (CI), -18.14, -10.17], P < 0.00001). MEBO may be effective for treating DFU. However, a firm conclusion could not be reached because of the poor quality of the included trials. Further trials with higher quality are justified.
Key words: Exposed wound ointment (MEBO), diabetic foot ulcers (DFU), recombinant bovine, basic fibroblast growth factor (rb-bFGF), vacuum sealing drainage (VSD).
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0